Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 10, 2004, Pages 765-771

  Balke, B ^a   Hoy, L ^a   Weissbrodt, H ^a   Haussler S ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYSTIC FIBROSIS; DILUTION; LABORATORY AUTOMATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AUTOMATION; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 8744259493     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1212-7     Document Type: Article

References (16)

1. Rosenstein BJ, Zeitlin PL (1998) Cystic fibrosis. Lancet 351:277-282
2. Demko CA, Byard PJ, Davis PB (1995) Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 48:1041-1049
3. Lyczak JB, Cannon CL, Pier GB (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222
4. Tummler B, Bosshammer J, Breitenstein S, Brockhausen I, Gudowius P, Herrmann C, Herrmann S, Heuer T, Kubesch P, Mekus F, Romling U, Schmidt KD, Spangenberg C, Walter S (1997) Infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Behring Inst Mitt 98:249-255
5. Chernish RN, Aaron SD (2003) Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 9:509-515
6. Koch C, Høiby N (2000) Diagnosis and treatment of cystic fibrosis. Respiration 67:239-247
7. Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA, Jones RN (2001) Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 39:257-260
8. Haussler S, Ziesing S, Rademacher G, Hoy L, Weissbrodt H (2003) Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 22:496-500
9. National Committee of Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. NCCLS, Wayne
10. Rajan S, Saiman L (2003) Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 17:47-56
11. Ramsey BW (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335:179-188
12. Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA, Jones RN (1999) Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 37:2987-2991
13. Drenkard E (2003) Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 5:1213-1219
14. Prince AS (2002) Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 347:1110-1111
15. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR (2001) Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 183:5395-5401
16. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary Biofilm Device: new technology for rapid identification of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776